adapalene / Generic mfg. - LARVOL DELTA

Identification of potent high-affinity secondary nucleation inhibitors of Aβ42 aggregation from an ultra-large chemical library using deep docking. (PubMed, Mol Syst Biol) - "The two most potent compounds showed potency better than adapalene, a previously reported potent inhibitor of Aβ aggregation. Consistent with the intended mechanism of action, these two compounds also proved to be high-affinity binders of Aβ fibrils with an equilibrium dissociation constant in the low nanomolar range in surface plasmon resonance experiments. These results provide evidence that structure-based docking methods based on deep learning represent a cost-effective and rapid strategy to identify potent hits for drug development targeting protein misfolding diseases."

Journal • Alzheimer's Disease • CNS Disorders • Proteinopathy • Aβ42

The Dark Side of Oral Antibiotics: Adverse Events of Consideration in Dermatology. (PubMed, J Drugs Dermatol) - "To mitigate these risks, dermatologists should prioritize narrow-spectrum antibiotics and incorporate combination topical therapies containing benzoyl peroxide (BPO), such as the triple-combination of clindamycin, adapalene, and BPO, to help curb antibiotic resistance. Prudent antibiotic use, combined with topical regimens utilizing BPO, optimizes treatment outcomes while minimizing systemic adverse effects and resistance. Ongoing education and research are essential to refine prescribing practices that balance therapeutic benefits with long-term patient and public health."

Adverse events • Journal • Review • Acne Vulgaris • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Oncology

The CML and the ALL inducing isoforms of BCR::ABL1 differ for the induction of genomic instablity (ASH 2025) - "These two isoforms differin the presence of the oncogenic pleckstrin- and DBL-homology domains (DH and PH) in p210BCR::ABL1...It is not yet clear whether GI may be independent of ABL1 kinase activity, a target ofTKI. It has to be confirmed by clinical studies."

Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • ETV6 • PBX1 • PLEK

Virtual screening of drugs against multiple targets of Alzheimer's disease. (PubMed, J Alzheimers Dis) - "BackgroundDrug repurposing offers a rapid, cost-effective approach for discovering therapies against multiple targets.ObjectiveHere, we screen virtual ligand libraries consisting of 3468 approved drugs against 11 protein targets associated with Alzheimer's disease (AD).MethodsWe employ blind molecular docking, and target amyloid-β (Aβ), microtubule-associated protein tau (MAPT), Apolipoprotein E4 (APOE4), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid-β protein precursor (AβPP), β-secretase (BACE1), brain-derived neurotrophic factor (BDNF), presenilin 1 (PSEN1) and 2 (PSEN2), and α-synuclein (SNCA) proteins using AutoDock Vina.ResultsNotably, multitarget binding recurs among the top-10 ligands with Ergotamine and Dihydroergotamine potentially binding 8; Dutasteride 7; Drospirenone and Nilotinib 6; Adapalene and Conivaptan 5; Bromocriptine 4; and Rolapitant, Irinotecan, Plerixafor, Saquinavir, and Telmisartan 3, out of 11 protein targets. Likewise,..."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension • Inflammation • Pain • APOE • BDNF • MAPT • SNCA

A Novel Cationic Niosome Formulation for Topical Delivery of Adapalene. (PubMed, Biomed Res Int) - "The in vitro release profile showed that 73 ± 2.1% of Ada was released from the niosomal hydrogel within 24 h. Results from the cell viability and Draize tests indicated that the Ada-Nio hydrogel can be considered a safe and effective dermal agent for acne treatment. Niosomal hydrogel formulations appear to be safe, effective, and promising nanocarriers for the dermal delivery of Ada."

Journal • Acne Vulgaris

Adapalene as an Anticancer Agent: A Systematic Review and Meta-Analysis of In Vitro and In Vivo Studies. (PubMed, Eur J Pharmacol) - "In conclusion, Adapalene shows potential as a promising drug repurposing candidate with anti-cancer activity. However, the heterogeneity and publication bias in the included studies highlight the need for further research."

Journal • Preclinical • Retrospective data • Review • Acne Vulgaris • Eye Cancer • Oncology • Retinal Disorders • Solid Tumor

13-cis-retinoic acid modulates porcine ovarian granulosa cell differentiation via retinoic acid signaling-FoxA1 axis: Implications for ovarian follicular development and luteinization. (PubMed, Theriogenology) - "13cRA promoted RARβ/RXRβ receptor heterodimer formation, with pharmacological activation (Adapalene) potentiating LHR and PGR expression and receptor knockdown diminishing their expression...13cRA-mediated FoxA1 expression suppression occurred through CRABP2-dependent nuclear shuttling and RARβ/RXRβ receptor heterodimer activating, with combinatorial modulation of CRABP1/CYP26 system components (CYP26A1 and CYP26B1) significantly altering FoxA1 regulatory dynamics. Finally, we conclude that 13cRA can inhibit FoxA1 expression through RA signaling molecules (CRABP2, RARβ/RXRβ heterodimer, CRABP1, CYP26A1 and CYP26B1) and thus promote the differentiation of porcine ovarian granulosa cells."

Journal • Preclinical • Oncology • CRABP2 • CYP26A1 • FOXA1 • PGR

Clascoterone Stability When Combined with Topical Acne Medications In Vitro. (PubMed, Dermatol Ther (Heidelb)) - "Clascoterone demonstrated consistent and reproducible stability in the presence of other topical acne medications."

Journal • Preclinical • Acne Vulgaris • Dermatology

A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations. (PubMed, Pharmaceuticals (Basel)) - "For acne vulgaris, reductions in inflammatory and noninflammatory lesions were comparable to those of topical retinoids/adapalene, and tolerability was superior in some studies...In melasma and other dyschromias, 20% cream demonstrated efficacy similar to hydroquinone, exhibiting a favorable safety profile...AzA remains a versatile and well-tolerated dermatologic agent whose performance is strongly vehicle-dependent. Rational selection and engineering of carriers, particularly DES-integrated polymeric and lipid systems, can mitigate solubility and permeability limitations, enhance skin targeting, and reduce irritation in the treatment of acne and rosacea."

Journal • Review • Acne Vulgaris • Dermatology • Dermatopathology • Rosacea

A Mechanistic Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach Informed by In Vitro and Clinical Studies for Topical Administration of Adapalene Gels. (PubMed, Pharmaceutics) - "Clinical evaluation revealed formulation-dependent differences in adapalene's effects on measured skin parameters, with distinct pharmacodynamic profiles observed for each gel formulation. The overall study gave us a detailed insight into potential effects of formulation on the dermal pharmacokinetics and pharmacodynamics of adapalene using three marketed gels."

Journal • PK/PD data • Preclinical • Acne Vulgaris • Dermatology

Effectiveness and tolerability of adapalene cream 0.1% in the treatment of female skin ageing: A randomised controlled trial. (PubMed, Indian J Dermatol Venereol Leprol) - "Limitations Small sample size, short treatment follow-up period, and single-centre validation Conclusions Adapalene cream 0.1% cream significantly improved signs of skin ageing, particularly wrinkles and pigmentation, and was well-tolerated. It can be a promising treatment for skin ageing."

Clinical • Journal • Acne Vulgaris • Dermatology

Discovery of platelet glycoprotein VI receptor antagonists and their neuroprotective activity: an in silico, in vitro, and in vivo study. (PubMed, 3 Biotech) - "Future studies focusing on the adapalene and ranolazine molecular mechanisms, bleeding risk, dose titration, and long-term safety while managing thrombotic disorders have to be investigated. The online version contains supplementary material available at 10.1007/s13205-025-04530-z."

Journal • Preclinical • Cardiovascular • CNS Disorders • Hematological Disorders • Neuroblastoma • Oncology • Solid Tumor • Thrombosis • CASP3 • HIF1A • SYK

Congenital Milia and Multiple Malformations in an Infant: A Case of Oral-Facial-Digital Syndrome Type 1 (EADV 2025) - "Congenital milia can be managed with topical retinoids such as tretinoin or adapalene to promote skin turnover. Because overlap of the clinical features between subtypes is common, classification of a specific patient can be difficult. However, OFD1 can be distinguished from other types by its characteristic milia. Observed in about 30% of patients with OFD1."

Clinical • Alopecia • Dermatology • Genetic Disorders • Immunology • Infectious Disease • Pediatrics • OFD1

Auto-crosslinked Hyaluronic Acid As Adjuvant Skin booster for Facial Melasma with Stage 1 Exogenous Ochronosis in Fitzpatrick Skin Type IV Adult Female (EADV 2025) - "At night, two creams containing 10% alpha-hydroxy acid and 0,1% adapalene were used on alternate weeks for 1 month... Skin booster auto-crosslinked HA as an adjuvant to topical therapy showed good and satisfactory results. Therefore, it can be considered for further research in melasma-associated with EO cases."

Clinical • Dermatology • Dermatopathology

Persistent pruritic axillary papules in a young female patient – a case of Fox-Fordyce disease (EADV 2025) - "Low potency TCS, topical clindamycin and calcineurin inhibitors are suggested as the first line of therapy, whereas topical retinoids and intralesional CS are suggested as the second line. Despite adapalene intolerability, our patient had a good initial response to TCS monotherapy and is currently in follow-up. In case of poor further treatment response, oral isotretinoin is planned as the next step in therapeutic approach along with topical therapy."

Clinical • Aesthetic Medicine • Inflammation • Rare Diseases

Childhood granulomatous periorificial dermatitis – a case report with dermoscopic and reflectance confocal microscopy clues (EADV 2025) - "According to the patient's mother, prior empirical treatment with topical tacrolimus did not result in a clinical improvement...The patient experienced marked clinical improvement following an 8-week course of systemic and topical erythromycin in association with topical metronidazole and adapalene... This case demonstrates diagnostic difficulties associated with CGPD. While none of the non-invasive imaging modalities provides specific findings for CGPD, combined use of dermoscopy and RCM may help to narrow the differential diagnosis by indicating a granulomatous process. Treatment of CGPD is challenging."

Case report • Clinical • Dermatitis • Dermatology • Immunology

Azelaic Acid-Based Chemical Peeling Combined with Mandelic Acid and Lactic Acid for Mild-to-Moderate Acne Vulgaris: A Randomized Controlled Trial (EADV 2025) - "The control group (n=10) applied 0.1% adapalene gel topically, twice daily... The novel azelaic acid-based combination peeling demonstrated significant clinical improvement in acne lesions, reduction in sebum secretion, and enhancement of skin barrier function, with favorable tolerability. This treatment represents a promising alternative for patients intolerant to traditional acidic peels or topical retinoids."

Clinical • Acne Vulgaris • Aesthetic Medicine • Dermatology

Changes in skin barrier function caused by the topical retinoid adaplelene 0.1% in the treatment of mild to moderate acne vulgaris. (EADV 2025) - "Treatment with local retinoid improved skin barrier function - TEWL significantly decreased by 36.6% after 2 months of 0.1% adapalene therapy, indicating improved barrier function (p = 0.04). Although the pH of the skin initially increased from 5.47 to 5.87, indicating a temporary weakening of the barrier. At the 2 month mark, the pH normalized to 5.4, within the healthy range (4.5-5.5), also, confirming the improvement of the function of the skin barrier (p=0.016)."

Acne Vulgaris • Dermatology • Pruritus

Dihydromyricetin exerts dual anti-acne actions by suppressing Propionibacterium acnes proliferation and host inflammatory responses via TLR2/NF-κB/MAPK pathway inhibition. (PubMed, Eur J Pharmacol) - "In a murine acne model, topical application of 0.1% DMY gel attenuated ear edema, decreased inflammatory cell infiltration (macrophages, neutrophils, CD4+ and CD8+ T cells), and reduced bacterial loads comparable to standard treatments (adapalene and clindamycin). Molecular docking revealed DMY binds TLR2 via hydrogen bonds with TYR-326 and LYS-347 residues. These findings establish DMY as a novel dual-functional agent against acne that simultaneously targets bacterial proliferation and host inflammatory pathways through TLR2/NF-κB/MAPK axis modulation."

IO biomarker • Journal • Acne Vulgaris • Dermatology • Inflammation • CD4 • CD8 • CXCL8 • IL1B • MAPK8 • TLR2 • TNFA

Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Badr University

New P4 trial • Acne Vulgaris • Dermatology

Comparative efficacy of clindamycin phosphate with benzoyl peroxide versus clindamycin phosphate with adapalene in acne vulgaris: a systematic review and meta-analysis. (PubMed, Sci Rep) - "CLIN/BPO also resulted in fewer application site side effects (OR = 0.33, 95% CI: 0.23-0.47, p < 0.001). However, no significant differences were observed between the groups for reducing inflammatory (MD = 1.34,"

Clinical • Journal • Retrospective data • Review • Acne Vulgaris • Dermatology

Targeting the RARα-Gankyrin-PI3K axis with retinoid analogs to modulate autophagy in breast cancer cells: Computational insights and experimental validation. (PubMed, Comput Biol Chem) - "In addition, it suppressed lysosomal activity by 2.73-fold in MCF7 and 2.52-fold in MDA-MB-468, as demonstrated by lysotracker assays. These findings underscore the potential of Adapalene as a multi-targeted modulator of RARα-PI3K signaling, effectively disrupting autophagy and cancer cell survival mechanisms in luminal and triple-negative breast cancer cells."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PIK3CA • RARA

Importance of Carnitine in Dermatology (CDA 2025) - "Topically, carnitine has shown efficacy in reducing sebum, decreasing hyperpigmentation post- laser treatment, improving skin tolerability with adapalene in acne, reducing acne severity, and enhancing quality of life...Orally, carnitine has proven effective in reducing inflammation, alleviating isotretinoin-related liver and muscle effects, easing muscle spasms in vismodegib patients, countering wasting in pemphigus vulgaris during glucocorticoid therapy, and improving adipocytokines, mental health and inflammatory markers in PCOS. It has also shown benefits in preventing cardiomyopathy progression in severe recessive dystrophic epidermolysis bullosa, reducing advanced glycation end products, and improving walking distance and ulcer healing in peripheral vascular disease. Conclusion Carnitine and its derivatives have therapeutic potential in dermatology, offering benefits both topically and orally, warranting further exploration of their clinical applications."

Acne Vulgaris • Atopic Dermatitis • Cardiomyopathy • Cardiovascular • Complement-mediated Rare Disorders • Dermatitis • Dermatology • Fibrosis • Hereditary Angioedema • Immunology • Infectious Disease • Melanoma • Metabolic Disorders • Pemphigus Vulgaris • Peripheral Arterial Disease • Polycystic Ovary Syndrome • Primary Immunodeficiency • Pruritus • Psoriasis • Sarcoidosis • Scleroderma • Solid Tumor • Systemic Sclerosis

Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V (clinicaltrials.gov) - P1/2 | N=23 | Completed | Sponsor: Indonesia University

New P1/2 trial • Acne Vulgaris • Dermatology

Comparison of Effectiveness of Topical Retinoids Versus Liquid Nitrogen in Treatment of Plantar Warts(Viral Infection) (clinicaltrials.gov) - P4 | N=98 | Recruiting | Sponsor: Khyber Teaching Hospital

New P4 trial • Dermatology • Infectious Disease